^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Hormone Receptor Negative Breast Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The effect of eribulin treatment for patients with HER2-low breast cancer
Published date:
12/02/2023
Excerpt:
In this study, we investigated the effect of eribulin for patients with HER2-low breast cancer….In HR-negative/HER2-low group, PFS was improved by eribulin treatment...
